Good evening and welcome to Markets Desk, your close-of-day read on what's moving markets and the broader landscape.
Tesla is under fresh scrutiny tonight as a Business Insider investigation details missing fatal crash data, raising serious questions about the company's Autopilot transparency. Survivor Dillon Angulo, injured in a two thousand nineteen Key Largo crash, says he felt like a test subject, intensifying regulatory pressure on the automaker's autonomous driving program.
Shifting to geopolitics with direct market implications, the United States has formally notified European allies of a partial NATO force withdrawal, leaving capability gaps that Germany's defense minister Boris Pistorius says Berlin will move to fill. The development is rattling defense sector positioning across European equity markets and adding uncertainty to transatlantic security architecture.
In biotech, a deal worth watching: Gannet BioChem has entered a development partnership with Serina Therapeutics to advance SER-two fifty two, an investigational therapy targeting advanced Parkinson's disease. Clinical-stage partnerships like this one often serve as early signals of pipeline confidence, and investors will be watching Serina's upcoming trial milestones closely for any catalyst.
That's the tape. Markets Desk, signing off the floor.
